Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 9/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 5/20 | 0.38 |
| ▸ | CCR2 | P41597 | 3/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148343 | 0.91 | TACR1 (0.40) | TACR1SERPINE1CETPCCR2 | |
| SCHEMBL5148349 | 0.90 | CETP (0.41) | TACR1SERPINE1CETPCCR2 | |
| SCHEMBL5147175 | 0.90 | TACR1 (0.46) | TACR1SERPINE1CCR2 | |
| SCHEMBL5148330 | 0.89 | CETP (0.44) | TACR1SERPINE1CETP | |
| SCHEMBL5150794 | 0.88 | SERPINE1 (0.47) | TACR1SERPINE1CETP | |
| SCHEMBL5149890 | 0.87 | TACR1 (0.39) | TACR1SERPINE1CETPCCR2 | |
| SCHEMBL5148326 | 0.87 | TACR1 (0.39) | TACR1SERPINE1CCR2 | |
| SCHEMBL5148372 | 0.83 | CETP (0.43) | TACR1SERPINE1CETP | |
| SCHEMBL5148332 | 0.83 | SERPINE1 (0.37) | TACR1SERPINE1CCR2 | |
| SCHEMBL1893337 | 0.81 | TACR1 (0.44) | TACR1SERPINE1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | TACR1 1329/4885SERPINE1 90/4885CETP 1/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | TACR1 656/4885SERPINE1 423/4885CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.